Bitran J D, Kinzie J, Sweet D L, Variakojis D, Griem M L, Golomb H M, Miller J B, Oetzel N, Ultmann J E
Cancer. 1977 Jan;39(1):342-6. doi: 10.1002/1097-0142(197701)39:1<342::aid-cncr2820390151>3.0.co;2-9.
Twenty of 65 patients with diffuse histiocytic lymphoma were identified by staging laparotomy as being in pathologic stages (PS) I, I(E), II, II(E). Six of the 20 patients were treated with total nodal, 10 with extended mantle, and four with involved-field radiotherapy. The survival rate and relapse-free survival at five years were 71% and 78%, respectively. All relapses occurred within the first year and were confined to patients with PS II disease and four or more sites of involvement. Accurate pathologic staging identifies patients who are potentially curable with radiotherapy. Further studies are required to determine the treatment necessary to achieve cure in PS II patients with more than four sites of involvement.
65例弥漫性组织细胞淋巴瘤患者中，有20例经分期剖腹探查确定为病理分期（PS）I、I（E）、II、II（E）期。这20例患者中，6例接受了全淋巴结放疗，10例接受了扩大斗篷野放疗，4例接受了受累野放疗。5年生存率和无复发生存率分别为71%和78%。所有复发均发生在第一年，且仅限于PS II期疾病且受累部位达4个或更多的患者。准确的病理分期可识别出有可能通过放疗治愈的患者。需要进一步研究以确定对受累部位超过4个的PS II期患者实现治愈所需的治疗方法。
